Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Antimicrobial resistance

Diagnostics 'single most important intervention' in tackling AMR, parliamentary committee hears

Lord Jim O’Neill and Dame Sally Davies have both told a House of Commons health and social care committee inquiry that diagnostics are essential to tackling antimicrobial resistance, despite very little progress being made in this area.

Lord Jim O’Neill

Source: Courtesy of the Office of Lord Jim O’Neill

Lord Jim O’Neill, who led an independent review into how to drive the development of new antibiotics, said that although there has been “lots of talking” about antimicrobial resistance, very little progress had been made in the area of diagnostics

Diagnostics are central to tackling antimicrobial resistance (AMR), agreed expert witnesses giving evidence to the House of Commons health and social care committee inquiry into progress on tackling the problem.

Lord Jim O’Neill, economist and former treasury minister, said that although there has been “lots of talking”, very little progress had been made in the area of diagnostics. O’Neill was appointed in 2014 by then prime minister, David Cameron, to lead an independent review into how to drive the development of new antibiotics.

“When I am asked what is the single most important intervention that would make a huge difference? It would be diagnostics — I think about it in terms of supply and demand,” he told MPs on 4 September 2018.

“We can get all the new drugs we want, but that will only work for a while until they become resistant — we need to permanently reduce the demand — particularly the inappropriate demand.”

Luciana Berger, Labour Party MP and committee member, asked the panel whether commissioning diagnostic testing in community pharmacies would be achievable and, if so, what resources would be required to ensure delivery.

O’Neill referred to a July 2016 trial of a ‘test and treat’ service for group A Streptococcus in Boots pharmacies in parts of London and Leicestershire. “I gather that’s no longer taking place because the cost per unit is too high relative to getting a pill, but from the early results I saw in terms of how many people stopped going to waste a doctors time, the results were highly encouraging,” he said.

“This is exactly why I believe it should be embedded at the core of every part of healthcare provision.”

Dame Sally Davies, chief medical officer for England, said that she agreed with O’Neill on the importance of diagnostics in tackling AMR.

“Better diagnosis is clearly part of the answer; whether it’s a lab test or an algorithm, I want to see much more use of diagnostics,” she told the committee.

But she said that there may be some doubt over the role of pharmacists in using algorithms as a diagnostic tool.

“Algorithms are pretty effective in general practice, but you might not want a pharmacist doing it — although I don’t see why a good pharmacist, a well-trained one, shouldn’t.”

O’Neill said that with the announcement of additional government funding for the health budget it would be the “perfect time” to devote “a lot of that” to diagnostics.

He said that the time and cost savings that could be made with state-of-the-art diagnostics would be “enormous”.

“My suggestion is that there should be a thorough survey or analysis done of what could be the system wide benefits of introducing state of the art diagnostics.”

He referred to his 2016 AMR review, which stated that, “by 2020, all antibiotic prescriptions will need to be informed by up-to-date surveillance information and a rapid diagnostic test wherever one exists”.

Davies also said that money needed to be spent on preventing infection by way of hand-washing and vaccines, as well as education, and that Public Health England planned to repeat its awareness campaign on antibiotics in autumn 2018.

But she added that “one of the more scary bits” of the threat of AMR was the development of new antimicrobials.

“We don’t pay enough for antibiotics that they’re looked after carefully and that also means we’re not getting new ones through,” she said.

“Pharmaceutical companies have been working with the Department [of Health and Social Care] — and there is now a proposal for a pilot of two early antibiotics to see if we can manage one of these — but this will need some resource, so we come back to resourcing being important.

“You won’t solve this from the [Department of Health and Social Care’s] budget — this is a wicked problem that is cross-sectoral and it will have to be solved with treasury funding, and no country can do it on its own.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205413

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Essentials of Economic Evaluation in Healthcare

    Essentials of Economic Evaluation in Healthcare

    An introduction to economic evaluation specific to healthcare, for those with little or no knowledge of economics. Covers cost effectiveness, cost utility and cost benefit analysis.

    £33.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Lord Jim O’Neill

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.